CD276 (B7-H3) Monoclonal Antibody (M3.2D7), PE, eBioscience™, Invitrogen™

Description

Description: The M3.2D7 monoclonal antibody was generated against and reacts with mouse B7-H3, a member of the B7 family of the Ig superfamily proteins. B7-H3 is reported to be expressed by antigen presenting cells and developing bone during embryogenesis. The ligand for B7-H3 has not yet been identified and it is thought that B7-H3 down-regulates T cell functions by engaging an unknown counter receptor on T cells. M3.2D7 stains mouse B7-H3 transfected cells and not mouse spleen cells. M3.2D7 also stains human B7-H3 transfected cells. Applications Reported: The M3.2D7 antibody has been reported for use in flow cytometric analysis. Applications Tested: This M3.2D7 antibody is offered in 2 formats: - μg size: has been tested by flow cytometric analysis of mouse B7-H3 transfected cells. This can be used at less than or equal to 0.5 μg per test. A test is defined as the amount (μg) of antibody that will stain a cell sample in a final volume of 100 μL. Cell number should be determined empirically but can range from 10^5 to 10^8 cells/test. It is recommended that the antibody be carefully titrated for optimal performance in the assay of interest. - test size: has been pre-titrated and tested by flow cytometric analysis of mouse B7-H3 transfected cells. This can be used at 5 μL (0.25 μg) per test.

CD276 is a member of the B7 family of co-stimulatory molecules also known as B7-H3. CD276 is a type I transmembrane protein that induces the proliferation of CD4+ and CD8+ T cells, enhances the generation of cytotoxic T cells and selectively stimulates the production of interferon gamma. Expression of CD276 can be induced on dendritic cells and monocytes by inflammatory cytokines, and is also widely expressed in peripheral tissues including the heart, kidney, testis and colon. In humans, CD276 exists as two isoforms which result from gene duplication and differential splicing. CD276 is reported to have therapeutic potential for the regulation of cell-mediated immune responses to cancer, particularly in conjunction with anti-angiogenic therapy.